NervGen Pharma Corp.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

As Stephen Rosen , head of the corporate practice in London at law firm Cooley observed, “We start 2022 in the rare position of the sector never having as high a profile amongst investors [as] it d

As we enter the third year of the COVID-19 pandemic, the pharma industry has begun to adapt and grow around its constraints and opportunities. After the all-hands-on-deck scramble in early 2020, busin